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Abstract
Objectives. To determine the population structure and antimicrobial 
sensitivity profile of carbapenem-resistant A. baumannii isolates from 
different hospitals of Lebanon.
Methods. Thirty-two isolates of A. baumannii were collected between 
Jan-June 2011 from three distant hospitals in Lebanon. Molecular 
identification was done by partial rpoB sequencing. The antibiotic 
susceptibility testing was determined by agar disc diffusion. MICs for 
imipenem, meropenem, colistin, tigecycline and sulbactam were also 
determined for imipenem resistant strains. Genetic testing was per-
formed using MLST.
Results. Thirty isolates were identified as A. baumannii according to 
the molecular identification test, of these 24 exhibited imipenem re-
sistance. Susceptibility profiles (susceptible vs. intermediate vs. resis-
tant) of these isolates were 0% vs.12.5% vs.87.5% for meropenem, 
8.3%vs.54.2%vs.37.5% for tigecycline and 8.3%vs.8.3%vs83.4% for 
sulbactam, respectively. All isolates (100%) were sensitive to colistin. 
All isolates (except one) belonged to international clone 2.
Conclusion. High prevalence of drug resistant of A. baumannii pauses 
a major risk for patients in Lebanon. Therefore, an effective antimi-
crobial treatment, strict infection control measurements and rational 
antibiotic use over in Lebanon are mandatory to control further ag-
gravation of the antibiotic resistance organisms in this country.
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Background
Over the past decade, the incidence of infections due 
to multidrug-resistant (MDR ) Acinetobacter species 
has been on the rise worldwide [1]. Nowadays, a 
clear association had been established between in-
fections caused by carbapenem-resistant Acineto-
bacter baumannii (A. baumannii) and increased 
mortality (crude mortality 26%-68%), morbidity, 
intensive care unit (ICU) , increased stay and cost 
[2, 3], thus making this organism a serious threat to 
our patients. MDR strains of A. baumannii were be-
ing recovered in recent years. Also,, Occurrence of 
MDR Acinetobacter has been recently documented 
in trauma centers and ICUs in USA and Europe [4, 
5,6], whereas few studies have reported on emer-
gence of MDR Acinetobacter in Lebanon and other 
Arab Middle East countries [7-10]. Our study was 
conducted to determine the population structure 
and antimicrobial resistance patterns among imi-
penem-resistant A. baumannii clinical isolates col-
lected from different hospitals in Lebanon. 
Materials and methods
Bacterial isolates
This prospective study was extended over six months 
period between January 2011 and June 2011. Three 
hospitals from various geographic areas in Lebanon 
participated in the study. The study protocol includ-
ed submission of non-duplicate carbapenem-resis-
tant Acinetobacter isolates obtained from different 
clinical specimens (Deep tracheal aspirate ,urine 
,wound , sputum). Each center tested its own iso-
lates for susceptibility to imipenem by disk diffusion 
method according to its own practice guidelines. 
Only imipenem-resistant isolates were submitted to 
our referral laboratory and included in the study. 
At the time of analysis, samples were sub-cultured 
on blood agar base media [BioRad, France] and re-
identification was carried out using Remel RapID NF 
Plus system [Remel, USA] according to the manufac-
turer’s guidelines. Molecular identification at species 
level was performed by partial sequencing of rpoB 
(RNA polymerase subunit B) gene (350 pb) [11].
Antimicrobial susceptibility testing
Confirmatory testing for imipenem resistance was 
done for all isolates by disc diffusion (10 μg) [Bio-
Rad, France]. The susceptibility for 12 other antibi-
otics [BioRad, France] was also tested by disc diffu-
sion according to the EUCAST guidelines [12].The 
following antibiotics discs were used :ticarcillin (75 
μg), ticarcillin/clavulanic acid (75/10 μg), piperacillin/
tazobactam (100/10 μg), ceftazidime (30 μg), cipro-
floxacin (5 μg), amikacin (30 μg), gentamicin (10 μg), 
tobramycin (10 μg), netilmicin (10 μg), cotrimoxazole 
(1.02-23.75 μg), colistin (50 μg), and doxycycline (30 
μg). The minimal inhibitory concentrations [MICs] 
were determined for imipenem [Merck Sharp & 
Dohme], meropenem [Astra Zeneca Pharmaceuti-
cals], tigecycline [Pfeizer] and ampicillin-sulbactam 
[Sandoz] using the microdilution on Mueller-Hinton 
agar [BioRad, France] according to the protocol pro-
posed by Courvalin et al. [13]. Whereas, colistin MIC 
was determined by Etest [ Biomerieux France]. Only 
A. baumannii isolates found to be resistant to imi-
penem were included in the MIC study. The suscep-
tibility to imipenem, meropenem and colistin was 
determined according to the EUCAST 2014 break-
points [14]. Susceptibility to tigecycline and sulbac-
tam was determined according to breakpoints rec-
ommended by Pachón-Ibáñez et al. [11, 14, 15] and 
García-Peñuela et al. [15, 16], respectively (Table 1). 
The American Type Culture Collection [ATCC] qual-
ity control strain Acinetobacter baumannii [ATCC 
19606] was used to ensure proper performance of 
the disk diffusion and MIC test.
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Molecular analysis
DNA extraction
After overnight growth on nutrient agar [Biolife, Mi-
lano, Italy], a loop full of the tested A. baumannii 
bacteria was suspended in 500 μl of sterile ultra-
pure water and the QIAamp DNA mini Kit [Qiagen, 
Hilden, Germany] was used for extraction according 
to the manufacturer’s guidelines. 
Multi-Locus Sequence Typing
The internal fragments of seven housekeeping genes 
including cpn60 (60-kDa chaperonin), fusA (elonga-
tion factor EF-G), gltA (citrate synthase), pyrG (CTP 
synthase), recA (homologous recombination fac-
tor), rplB (50S ribosomal protein L2) and rpoB were 
amplified and sequenced according to the Pasteur 
scheme available at the following site (http://www.
pasteur.fr/mlst). The different sequences were com-
pared to the existing alleles in Pasteur MLST Data-
base. The identification number for sequence types 
(ST) was given according to their allelic profiles. In 
order to compare our identified ST(s) to previous 
identified ST(s) present in MLST Database and to as-
sign them to their corresponding clonal complexes, 
an eBURST analysis was used (http://eburst.mlst.
net/). A clonal complex was defined as a group of 
similar ST sharing 6 identical loci within 7. 
Results
Bacterial isolates. Re-identification of all investi-
gated strains in our laboratory using remel tech-
nique showed that all 32 strains were belonged to 
A. calcoaceticus-A. baumannii complex (99% con-
fidence). Of these, 30 were identified as A. bau-
mannii and 2 as A. pitti strains according to the 
molecular identification based on partial rpoB se-
quencing, Only A. baumannii isolates were included 
for further analysis. The hospital repartition of A. 
baumannii isolates is shown in Table 2.
Genetic variability. MLST was performed on all 30 
A. baumannii strains to discover the genetic back-
ground of A. baumannii strains infected patients in 
Lebanon. Two sequence types ST2 and ST458 were 
identified. ST2 was the major sequence type pres-
ent in 29 strains, whereas ST458 was found sporadi-
cally in one strain. By eBURST analysis (Figure 1) 
of MLST database (last updated 07.08.2014), ST2 
was the founder of the biggest and principal clonal 
complex (known as clonal complex 2) formed up to 
33 single locus variants [SLV]. ST458 was a singleton 
and no similar ST has been identified yet. Those STs 
that can’t be linked to any other in the sample are 
termed singletons and appear as unlinked points 
Table 1. Susceptibility breakpoints (µg/ml) of the tested antimicrobials
Antibiotic Sensitive Intermediate Resistance Reference
Colistin ≤ 2 - > 2 12
Imipenem ≤ 2 ]2 – 8] > 8 12
Meropenem ≤ 2 ]2 – 8] > 8 12
Sulbactam ≤ 4 8 ≥ 16 15
Tigecycline ≤ 2 4 ≥ 8 14
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Antibiotic MICs(µg/ml)
Strain no. Hospital ST TIC TCC TZP CAZ IMI SXT CS GEN TM AMK NET CIP DOX CS IMI MER TIG SAM
CMUL 016 1 2 R R R R R R S R R R R R R 0.047 64 64 8 32
CMUL 017 1 2 R R R R R S S R R R R R R 0.032 64 128 8 32
CMUL 018 1 2 R R R R R R S R R R R R R 0.047 64 128 8 32
CMUL 019 1 2 R R R R R R S R R R R R R 0.047 32 64 4 16
CMUL 020 1 2 R R R R R R S R R R R R R 0.032 32 8 4 16
CMUL 021 2 2 I R I R S R S R S S S R R
CMUL 023 2 2 R R R R S R S R S S S R R
CMUL 024 2 2 R R R R R R S R S R R R R 0.047 32 4 4 8
CMUL 025 1 2 R R R R R R S R R R R R R 0.032 128 128 4 32
CMUL 026 1 2 R R R R R R S R R R R R R 0.032 64 128 8 32
CMUL 027 1 2 R R R R R R S R R R R R R 0.032 64 >128 4 32
CMUL 028 1 2 R R R R R R S R R R R R R 0.032 64 64 8 32
CMUL 029 1 2 R R R R R R S R R R R R R 0.032 64 64 8 32
CMUL 030 3 2 R R I R R R S S S S S R R 0.032 16 8 4 4
CMUL 032 2 2 R R I R S R S R S S S R R
CMUL 033 1 2 R R R R R R S R R R R R R 0.094 64 64 16 32
CMUL 034 1 2 R R R R R R S R R R R R R 0.047 >128 32 4 16
CMUL 035 1 2 R R R R R R S R R R R R R 0.047 32 32 8 8
CMUL 036 1 2 R R I R S R S R S S S R S
CMUL 037 1 2 R R R R R R S R R R R R R 0.047 64 64 16 16
CMUL 038 1 2 R R R R R R S R R R R R R 0.032 64 >128 4 16
CMUL 039 1 2 R R R R R R S R R R R R R 0.032 64 32 4 32
CMUL 040 1 2 R R R R R R S R R R R R R 0.047 32 32 4 16
CMUL 041 1 2 R R R R R R S R R R R R R 0.032 32 32 4 16
CMUL 042 1 2 R R R R R R S R R R R R R 0.047 64 32 4 16
CMUL 048 3 2 R R R R R R S R R R R R R 0.032 128 128 2 32
CMUL 049 2 2 R R I R S R S R S S R R R
CMUL 050 2 458 S S S S S S S S S S S S S
CMUL 052 3 2 R R R R R R S R S R R R R 0.032 32 16 4 4
CMUL 053 3 2 R R R R R R S R R R R R R 0.032 64 128 2 128
Table 2. Hospital repartition, sequence types and antibiotic susceptibility of A. baumannii strains 
TIC (ticarcillin), TCC (ticarcillin/clavulanic acid), TZP (piperacillin/tazobactam), CAZ (ceftazidime),IMP (imipenem), SXT (trimethoprim/
sulfamethoxazole), CS (colistin), GEN (gentamicin), TM (tobramycin), AMK (amikacin), NET (netilmicin), CIP (ciprofloxacin), DOX 
(doxycycline), MER (meropenem), TIG (Tigecycline) and SAM (sulbactam).
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Antimicrobial susceptibility
Table 2 shows the antibiotic susceptibility profile of 
all A. baumannii strains to various antibiotic classes. 
A total of 24 imipenem-resistant strains was de-
tected and the rest 6 strains were imipenem-sus-
ceptible. Further susceptibility study of these 24 imi-
penem-resistant strains was also done by checking 
MIC of colistin, imipenem, meropenem, sulbactam 
and tigecycline (Table 2). A total of 21 A. bauman-
nii isolates (87.5 %) were resistant to meropenem, 
and 12.5 % (3 ) showed intermediate susceptibility. 
For tigecycline, 2 (8.3 %) of imipenem-resistant A. 
baumannii isolates were susceptible, 54.2 % (13 ) 
were intermediate and 37.5 % (9) were resistant. 
All the resistant strains belonged to sequence type 
2. They were found among the different hospitals 
with no specific distribution. All imipenem-resistant 
A. baumannii isolates (100 %) were susceptible to 
colistin, whereas 83.4 % (20) of the tested isolates 
were resistant to sulbactam, 8.3% (2) had interme-
diate susceptibility, and also 8.3 % (2) were suscep-
tible to sulbactam. 
Discussion
This study demonstrates important results due to 
the high resistance rates found to common used 
antimicrobials. All the A. baumannii isolates (except 
one) belong to international clone 2 (clonal complex 
2) , while 82.8 % (24/29) isolates were imipenem-
resistant. The clone notion in A. baumannii has been 
appeared for the first time in 1996 when Dijkshoorn 
et al. found two clones distributed in different hos-
pitals in northwestern Europe and designated them 
as European clone I and II [17]. After that, these two 
clones and another clone (designated as European 
clone III) [18] have been identified throughout the 
world and then named international clones (I to III) 
[19]. The dominance of international clone 2 in our 
collection fits to the global situation where a shift 
toward this clone has been observed worldwide. It 
was the largest and the widely distributed clone in 5 
continents [20]. The successful emergence of inter-
national clone 2 has been attributed to the frequent 
acquisition of antimicrobial resistance determinants 
[20]. Further studies using micro-epidemiolgical typ-
ing methods like Pulsed Field Gel Electrophoresis are 
required to evaluate the homogeneity or heteroge-
neity of the international clone 2 in Lebanon. 
Figure 1. Population snapshot drawn by 
eBURST software by analysis of 587 ST(s) 
present in MLST Pasteur Database and our 
identified ST(s). The red circle means an 
identified sequence type in this study.
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A. baumannii is an opportunistic pathogen with 
widespread antimicrobial resistance patterns to 
commonly used antimicrobials such as; aminoglyco-
sides, extended-spectrum cephalosporins, beta-lac-
tams/sulbactam, antipseudomonal penicillins/beta-
lactamase inhibitors, cotrimoxazole, carbapenems, 
fluoroquinolones, polymixins, and tetracycline. Ma-
giorakos et al. has categorized MDR Acinetobacter 
into 3 groups according to the various resistance 
patterns among [20]. MDR organisms are defined 
as strains that are resistant to at least 3 antimicrobi-
als representing at least 3 classes. Extensively drug 
resistant [XDR] organisms are strains susceptible not 
to more than 2 classes , and Pandrug resistant or-
ganisms are strains that are resistant to all classes 
[21]. In addition to being resistant to carbapenems, 
beta-lacams/beta-lactamase inhibitor combinations, 
quinolones, aminoglycosides and cotrimoxazole, 
only 8.3 % were susceptible to tigecycline and sul-
bactam. This result is alarming issue since this is an 
evidence of emergence of XDR A. baumannii in our 
health care facilities, and colistin become the last re-
sort for treatment of XDR A. baumannii in Lebanon. 
 It is important to note that resistance to colistin 
has been reported in some countries [22]. Interest-
ingly, colistin hetero-resistance is much higher than 
colistin-resistance, and it is also difficult to be de-
tected. First colistin hetero-resistance in A. bauman-
nii had been shown by Li et al. [22]. In this study, 
colistin-susceptible A. baumannii strains showed 
early concentration-dependent killing and that sub-
optimal doses of colistin induce resistance. There is 
two recent studies from Arab Middle East countries 
reported A. baumannii colistin resistance isolates, 
Kuwait (12 %) and Egypt (5 %) (7, 23]. When inves-
tigating the dosing regimens in the corresponding 
Lebanese hospitals during the year preceding the 
study period, the doses used varied between 1MU 
every 12 hours and 1MU every 8 hours and rarely 
reached 2MU every 8 hours, and these doses were 
lower than that recommended by Michalopoulos 
and Falagas (3 million IU; 240 mg CMS) every 8 
hours as the optimal dose of colistin for critically ill-
patients with normal renal function [24]. Different 
dosing, however, was recommended by the manu-
facturers of European colistin products is 50,000 to 
75,000 IU/kg/day of CMS in 2-3 divided doses. This 
study is recommending to investigate doses higher 
than the doses mentioned in the leaflet of manufac-
turers or the regimens used in Lebanon to maintain 
a full efficacy of colistin. 
Tigecycline activity, on the other hand, is compro-
mised by multidrug efflux pump systems such as 
AdeABC PUMP [ 25]. Peleg et al. showed that the 
gene coding for the production of this pump can 
be up regulated under antibiotic pressure causing a 
rapid rise in MIC to tigecycline upon in vitro passage 
[26]. Thus, the high rates of tigecycline resistance 
encountered in our study may be due to the poor 
understanding of the drug’s pharmacokinetics and 
pharmacodynamics in different infection sites like 
the bloodstream, and/or in special populations of 
patients like the critically ill, the obese and many 
others conditions [27].
Due to shortage of new antimicrobials against XDR 
Acinetobacter, older drugs like sulbactam are con-
sidered. Sulbactam possesses an intrinsic activity 
against A. baumannii independent of the accompa-
nying beta-lactam present in commercial combina-
tions [ 28-32]. The activity of sulbactam is mediated 
by binding of the drug to penicillin-binding protein 
2 [PBP2] [2]. The clinical usefulness of sulbactam was 
proven in several studies that showed no inferior-
ity to imipenem and better eradication rates than 
comparators in treating non-life threatening infec-
tions caused by imipenem- and sulbactam-sensitive 
A. baumannii strains [28,32]; however, all the stud-
ies had a drawback of having a small number of 
investigated patients.
THE INTERNATIONAL ARABIC JOURNAL 
OF ANTIMICROBIAL AGENTS
2014
Vol. 4 No. 1:4
doi: 10.3823/746
© Under License of Creative Commons Attribution 3.0 License 7
Despite sulbactam-ampicillin being out of the mar-
ket for the past 20 years, almost Acinetobacter 
strains were resistant to this combinations. This can 
be explained by the fact that both sulbactam and 
beta-lactams act by binding PBP2 and mutations 
in the PBP2 gene, selected by antimicrobial pres-
sure, lead to cross-resistance to both. In a recent re-
port, the Surveillance Network in the United States 
showed that resistance patterns of Acinetobacter 
to sulbactam combinations vary widely with geo-
graphic distribution toward an increase in resistance 
rate from 10.6% in 1999 to 25% in 2010 [32], still 
much lower than our reported resistance rate.
Conclusion
With the absence of an effective therapy, the wide 
spread of XDR A. baumannii in our Lebanese health 
care facilities poses a great danger to patients by 
increasing mortality, morbidity and hospital stay. 
Combination therapy of colistin with rifampicin or 
minocycline might be effective but has yet to be 
proven against XDR A. baumannii strains. Strict in-
fection control measurements and rational antibiot-
ic use are mandatory to control further aggravation 
of the antibiotic resistance in Lebanon.
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